Drug Approval | July 22, 2024
Briefs: Zydus Lifesciences and Divi's Laboratories
Zydus receives final approval from USFDA for its NDA Zituvimeta, extended-release tablets
Zydus receives final approval from USFDA for its NDA Zituvimeta, extended-release tablets
The built-in AI-trained algorithms will empower users to proactively intervene when their glucose levels require attention and before a complication can even occur
GL0034 administered once-weekly confirmed clinically meaningful weight loss and improved glucometabolic parameters over a 4-week treatment period in individuals with obesity
SYNERGY-NASH results were presented at the European Association for the Study of the Liver Congress 2024 and simultaneously published in The New England Journal of Medicine
Canagliflozin and Metformin Hydrochloride Tablets are used to treat type 2 diabetes mellitus
Largest investment in active pharmaceutical ingredient manufacturing of synthetic medicines in U.S. history
Data support the potential of Dupixent as the first new treatment approach in more than a decade and first-ever targeted therapy for COPD
The company had earlier announced about the approval received from the MHRA for Liraglutide
Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus
Bayer has granted the non-exclusive rights to Sun Pharma to market and distribute a second brand of Finerenone under the brand name Lyvelsa
Subscribe To Our Newsletter & Stay Updated
